Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone

Abstract Background Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in ch...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alan H. Bryce, David Nimke, Christopher Young, Qiujun Shao, Nigel Rozario, Pinal Kamdar, Jasmina Ivanova, Irene Varghese, Maelys Touya
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-03-01
Edice:	Cardio-Oncology
Témata:	Androgen-receptor pathway inhibitor CV disease CV events Major adverse cardiac events mCRPC
On-line přístup:	https://doi.org/10.1186/s40959-026-00465-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!